
Opinion|Videos|February 6, 2025
Tyrosine Kinase Inhibitors to Prolong Efficacy of Anti-VEGF Therapies
Panelists explore how the introduction of tyrosine kinase inhibitors (TKIs) could affect the perceived benefits of the port delivery system, as these agents may offer an alternative approach to reducing injection burden while potentially providing broader therapeutic effects.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- If TKIs become available, how would this impact the relative benefits of PDS?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Q&A: The ARCHER trial and the importance of continued GA research
2
Frank Holz, MD, FEBO, FARVO, highlights new treatment developments at EURETINA
3
Challenges Reported by Young Physicians in Managing Geographic Atrophy and How these Shape Patient Care
4
The Retina TL;DR: Advancing sustained VEGF suppression with EYP-1901 with Jay S. Duker, MD
5